Maravai LifeSciences (MRVI) Reports In-Line Q3 EPS

Maravai LifeSciences (NASDAQ: MRVI) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $41.6 million versus the consensus estimate of $49.04 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Sonos partners with Škoda for audio system in new Peaq EV